Mereo BioPharma's top three insider shareholders as of March 23, 2026 are Denise Scots-Knight (Chief Executive Officer, 808.92K shares), Charles Sermon (General Counsel, 219.06K shares), Christine Ann Fox (Chief Financial Officer, 89.28K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Denise Scots-Knight | Chief Executive Officer | 808,921 | 0 | 16 Sep, 2024 |
| Charles Sermon | General Counsel | 219,061 | 0 | 16 Sep, 2024 |
| Christine Ann Fox | Chief Financial Officer | 89,285 | 0 | 16 Sep, 2024 |
| John A. Lewicki | Chief Scientific Officer | 78,630 | 0 | 16 Sep, 2024 |
| Alexandra Hughes-Wilson | See Remarks | 50,475 | 0 | 16 Sep, 2024 |
| Michael S Wyzga | 25,050 | 0 | 17 Jun, 2024 | |
| Jeremy Bender | 0 | 12,550 | 17 Jun, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Feb, 2026 | Michael S Wyzga | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Jeremy Bender | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Daniel Shames | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Anders Ekblom | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Pierre Jacquet | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Deepika Pakianathan | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Annalisa Jenkins | Share Options (Right to buy) | A | 66,000 | $0.00 | 66,000 | D | A |
| 26 Feb, 2026 | Annalisa Jenkins | Deferred Restricted Stock Units | A | 106,848 | - | 106,848 | D | A |
| 26 Feb, 2026 | Anders Ekblom | Deferred Restricted Stock Units | A | 133,560 | - | 133,560 | D | A |
| 26 Feb, 2026 | Marc J Yoskowitz | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |
| 26 Feb, 2026 | Pierre Jacquet | Deferred Restricted Stock Units | A | 106,848 | - | 106,848 | D | A |
| 26 Feb, 2026 | Jeremy Bender | Deferred Restricted Stock Units | A | 117,533 | - | 117,533 | D | A |
| 26 Feb, 2026 | Daniel Shames | Deferred Restricted Stock Units | A | 96,163 | - | 96,163 | D | A |
| 01 Feb, 2026 | Alexandra Hughes-Wilson | Share Options (Right to buy) | A | 183,750 | $0.00 | 183,750 | D | A |
| 01 Feb, 2026 | Christine Ann Fox | Share Options (Right to buy) | A | 315,750 | $0.00 | 315,750 | D | A |
| 01 Feb, 2026 | Charles Sermon | Share Options (Right to buy) | A | 315,750 | $0.00 | 315,750 | D | A |
| 01 Feb, 2026 | Denise Scots-Knight | Share Options (Right to buy) | A | 1,035,000 | $0.00 | 1,035,000 | D | A |
| 01 Feb, 2026 | John A. Lewicki | Share Options (Right to buy) | A | 139,913 | $0.00 | 139,913 | D | A |
| 01 Feb, 2026 | John A. Lewicki | Share Options (Right to buy) | A | 46,637 | $0.00 | 46,637 | D | A |